Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marla C Dubinsky

Showing results (201-210 of 286) with videos related to

Pageof 29
Sort By:
Journal of Crohn'S & Colitis|July 4, 2023
Major Adverse Cardiovascular Events by Baseline Cardiovascular Risk in Patients with Ulcerative Colitis Treated with Tofacitinib: Data from the OCTAVE Clinical ProgrammeStefan Schreiber, David T Rubin, Siew C Ng, et al.
The American Journal of Gastroenterology|August 13, 2021
A Comprehensive Literature Review and Expert Consensus Statement on Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel DiseaseAdam S Cheifetz, Maria T Abreu, Waqqas Afif, et al.
Journal of Patient-Reported Outcomes|July 1, 2025
Bowel urgency in ulcerative colitis: effect of baseline urgency and change in urgency in response to mirikizumabDavid B Clemow, Marla C Dubinsky, Simin K Baygani, et al.
Frontiers in Immunology|March 13, 2024
Corrigendum: Poor prognostic factors of pharmacokinetic origin predict outcomes in inflammatory bowel disease patients treated with anti-tumor necrosis factor-αElizabeth A Spencer, Marla C Dubinsky, Michael A Kamm, et al.
Frontiers in Immunology|March 13, 2024
Poor prognostic factors of pharmacokinetic origin predict outcomes in inflammatory bowel disease patients treated with anti-tumor necrosis factor-αElizabeth A Spencer, Marla C Dubinsky, Michael A Kamm, et al.
Inflammatory Bowel Diseases|November 5, 2025
Efficacy and Safety with Upadacitinib by Baseline Corticosteroid Use in Patients with Moderately to Severely Active Crohn's DiseaseMarla C Dubinsky, Geert D'Haens, Olivier Dewit, et al.
Current Medical Research and Opinion|July 10, 2025
Impact of moderate-to-severe ulcerative colitis and Crohn's disease on sexual activity: United States and European patient perspectives from the communicating needs and features of IBD experiences (CONFIDE) surveyMarla C Dubinsky, Alison Potts Bleakman, Stefan Schreiber, et al.
Inflammatory Bowel Diseases|October 12, 2004
A pilot study of adalimumab in infliximab-allergic patientsAdrienne Youdim, Eric A Vasiliauskas, Stephan R Targan, et al.
Inflammatory Bowel Diseases|September 26, 2025
Long-Term Ozanimod Therapy in Patients With Moderately Active Ulcerative Colitis After Failure of 5-Aminosalicylic AcidAndres Yarur, Peter Irving, Britta Siegmund, et al.
Crohn'S & Colitis 360|February 13, 2023
Impact of Bowel Urgency on Quality of Life and Clinical Outcomes in Patients With Ulcerative ColitisMarla C Dubinsky, Remo Panaccione, James D Lewis, et al.
Pageof 29

Showing results (201-210 of 286) with videos related to

Sort By:
Pageof 29
Journal of Crohn'S & Colitis|July 4, 2023
Major Adverse Cardiovascular Events by Baseline Cardiovascular Risk in Patients with Ulcerative Colitis Treated with Tofacitinib: Data from the OCTAVE Clinical ProgrammeStefan Schreiber, David T Rubin, Siew C Ng, et al.
The American Journal of Gastroenterology|August 13, 2021
A Comprehensive Literature Review and Expert Consensus Statement on Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel DiseaseAdam S Cheifetz, Maria T Abreu, Waqqas Afif, et al.
Journal of Patient-Reported Outcomes|July 1, 2025
Bowel urgency in ulcerative colitis: effect of baseline urgency and change in urgency in response to mirikizumabDavid B Clemow, Marla C Dubinsky, Simin K Baygani, et al.
Frontiers in Immunology|March 13, 2024
Corrigendum: Poor prognostic factors of pharmacokinetic origin predict outcomes in inflammatory bowel disease patients treated with anti-tumor necrosis factor-αElizabeth A Spencer, Marla C Dubinsky, Michael A Kamm, et al.
Frontiers in Immunology|March 13, 2024
Poor prognostic factors of pharmacokinetic origin predict outcomes in inflammatory bowel disease patients treated with anti-tumor necrosis factor-αElizabeth A Spencer, Marla C Dubinsky, Michael A Kamm, et al.
Inflammatory Bowel Diseases|November 5, 2025
Efficacy and Safety with Upadacitinib by Baseline Corticosteroid Use in Patients with Moderately to Severely Active Crohn's DiseaseMarla C Dubinsky, Geert D'Haens, Olivier Dewit, et al.
Current Medical Research and Opinion|July 10, 2025
Impact of moderate-to-severe ulcerative colitis and Crohn's disease on sexual activity: United States and European patient perspectives from the communicating needs and features of IBD experiences (CONFIDE) surveyMarla C Dubinsky, Alison Potts Bleakman, Stefan Schreiber, et al.
Inflammatory Bowel Diseases|October 12, 2004
A pilot study of adalimumab in infliximab-allergic patientsAdrienne Youdim, Eric A Vasiliauskas, Stephan R Targan, et al.
Inflammatory Bowel Diseases|September 26, 2025
Long-Term Ozanimod Therapy in Patients With Moderately Active Ulcerative Colitis After Failure of 5-Aminosalicylic AcidAndres Yarur, Peter Irving, Britta Siegmund, et al.
Crohn'S & Colitis 360|February 13, 2023
Impact of Bowel Urgency on Quality of Life and Clinical Outcomes in Patients With Ulcerative ColitisMarla C Dubinsky, Remo Panaccione, James D Lewis, et al.
Pageof 29